Imperial College London
Portrait Picture

Professor Mona El-Bahrawy

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Practice (Histopathology)
 
 
 
//

Contact

 

m.elbahrawy

 
 
//

Location

 

Department of HistopathologyHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Masood:2020:10.3390/cancers12123862,
author = {Masood, M and Grimm, S and El-Bahrawy, M and Yague, E},
doi = {10.3390/cancers12123862},
journal = {Cancers},
pages = {1--25},
title = {TMEFF2: A transmembrane proteoglycan with multifaceted actions in cancer and disease},
url = {http://dx.doi.org/10.3390/cancers12123862},
volume = {12},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Transmembrane protein with an EGF-like and two Follistatin-like domains 2 (TMEFF2) is a 374-residue long type-I transmembrane proteoglycan which is proteolytically shed from the cell surface. The protein is involved in a range of functions including metabolism, neuroprotection, apoptosis, embryonic development, onco-suppression and endocrine function. TMEFF2 is methylated in numerous cancers, and an inverse correlation with the stage, response to therapy and survival outcome has been observed. Moreover, TMEFF2 methylation increases with breast, colon and gastric cancer progression. TMEFF2 is methylated early during oncogenesis in breast and colorectal cancer, and the detection of methylated free-circulating TMEFF2 DNA has been suggested as a potential diagnostic tool. The TMEFF2 downregulation signature equals and sometimes outperforms the Gleason and pathological scores in prostate cancer. TMEFF2 is downregulated in glioma and cotricotropinomas, and it impairs the production of adrenocorticotropic hormone in glioma cells. Interestingly, through binding the amyloid β protein, its precursor and derivatives, TMEFF2 provides neuroprotection in Alzheimer’s disease. Despite undergoing extensive investigation over the last two decades, the primary literature regarding TMEFF2 is incoherent and offers conflicting information, in particular, the oncogenic vs. onco-suppressive role of TMEFF2 in prostate cancer. For the first time, we have compiled, contextualised and critically analysed the vast body of TMEFF2-related literature and answered the apparent discrepancies regarding its function, tissue expression, intracellular localization and oncogenic vs. onco-suppressive role.
AU  - Masood,M
AU  - Grimm,S
AU  - El-Bahrawy,M
AU  - Yague,E
DO  - 10.3390/cancers12123862
EP  - 25
PY  - 2020///
SN  - 2072-6694
SP  - 1
TI  - TMEFF2: A transmembrane proteoglycan with multifaceted actions in cancer and disease
T2  - Cancers
UR  - http://dx.doi.org/10.3390/cancers12123862
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000601698700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.mdpi.com/2072-6694/12/12/3862
UR  - http://hdl.handle.net/10044/1/86119
VL  - 12
ER  -
Download